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Case ReportsVenoarterial extracorporeal membrane oxygenation for right heart
failure complicating left ventricular assist device useMasashi Kai, MD, Gilbert H. L. Tang, MD, MSc, Ramin Malekan, MD, Steven L. Lansman, MD, PhD, and
David Spielvogel, MD, Valhalla, NYFrom 15% to 25% of patients have right heart failure
(RHF) develop after left ventricular (LV) assist device
(LVAD) placement,1 significantly increasing morbidity
and mortality.2 Right ventricular (RV) assist devices
(RVADs) may support RV function, but they have signifi-
cant limitations. We describe a novel management strategy
of using peripheral venoarterial extracorporeal membrane
oxygenation (ECMO),3 configured for easy explantation,
that may improve RV recovery and reduce mortality and
morbidity.CLINICAL SUMMARY
From March 2012 to March 2013, a total of 5 patients
with cardiogenic shock and biventricular failure supported
by venoarterial ECMO underwent Heartmate II (HM II)
LVAD implantation with ECMO support for RHF
(Table 1). Preoperative ECMO duration was 7.8 days
(3-17 days). Of the 5 patients, 3 had axillary arterial outflow
and the 2 with central cannulation had conversion to an arte-
rial outflow graft connected end to side to the HM II outflow
graft, which was exteriorized through the right side of the
chest (Figure 1).
To optimize systemic output, it is important to balance
the HM II and ECMO flows. In the operating room, inter-
ventricular septal position was assessed by transesophageal
echocardiography, and flows were adjusted to unload the
RV sufficiently while avoiding inadequate HM II preload
and yet augmenting systemic output. We found that
ECMO flows of 2 to 3 L/min, with the HM II speed set at
8400 rpm, will generally achieve this balance. In the inten-
sive care unit, inotrope and vasopressor use can be mini-
mized, which promotes normalization of peripheral
vascular resistance and aids RV, pulmonary, and visceral re-
coveries. We found that adjustments of HM II speed and
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The Journal of Thoracic and Cawas best augmented by increasing the volume rather than
by adjusting the ECMO flow. Heparin was administered
to achieve a target activated clotting time of 200 to 240
seconds.
All patients were successfully weaned from ECMO after
an average of 4.8 days of support, with no deaths, strokes, or
vascular complications. There was 1 in-hospital death.
Follow-up was 9.9  3.3 months and 100% complete.
Among the 4 patients who survived the HM II implantation
hospitalization, 1 underwent cardiac transplant, 1 is
currently awaiting transplant, 1 had LV recovery while
awaiting HM II explantation, and 1 died of stroke 6 months
after HM II placement.DISCUSSION
Although RVADs have played an important role for RHF
after LVAD implantation, associated mortality remains
high,2 and a number of factors, such as bleeding, infection,
and thromboembolism, may limit their usefulness in this
setting.
First, a major disadvantage of an RVAD in this setting is
that it does not unload the RV but rather increases RVafter-
load. In addition, if RVAD flow sufficiently increases pul-
monary arterial pressure, it may precipitate or increase
pulmonic insufficiency, exacerbating RV distention. On
the other hand, ECMO, by bypassing the right side of the
heart, does unload the RV and may promote RV healing
more efficiently than does an RVAD. A second potential
disadvantage of an RVAD is that it can exacerbate pulmo-
nary edema, because it can directly perfuse the lungs at
high flows and high pressures. Venoarterial ECMO drops
the pulmonary artery pressure by bypassing the lungs and
may thereby promote resolution of pulmonary edema.
Finally, by augmenting systemic perfusion and improving
venous drainage, ECMOmay lower the central venous pres-
sure more effectively, optimize end-organ perfusion, and
more effectively reverse hepatorenal and cardiorenal syn-
dromes. All our patients with HM IIs who received
ECMO support had their hepatic and renal injuries reversed.
A potential disadvantage of ECMO is that it can increase
LVafterload. In our cases, however, the patients also had an
LVAD, which was better able to handle afterload than a
failing LV would be. Another potential limitation of the
configuration that we describe here is that 2 pumps perfuse
the systemic circulation, increasing the risk of systemicrdiovascular Surgery c Volume 147, Number 3 e31
TABLE 1. Patient data (N ¼ 5)
Patient characteristics
Age (y, mean and range) 56.8 (50-64)
Male (No.) 3
Preoperative ECMO duration (d, mean and range) 7.8 (3-17)
Peripheral ECMO (No.) 3
Central ECMO (No.) 2
Ischemic cardiomyopathy (No.) 4
Dilated cardiomyopathy (No.) 1
Biventricular failure (No.) 5
Hypertension (No.) 4
Diabetes (No.) 3
Renal failure requiring dialysis (No.) 0
Peripheral vascular disease (No.) 1
Previous cardiac surgery (No.) 4
Concomitant procedures (No.)
Tricuspid valve repair 1
Patent foramen ovale closure 1
Case Reportsembolization. In this limited series, however, no patients
had any embolic events during ECMO support. We did
not find patients with HM II placement who were receivingFIGURE 1. Left ventricular assist device with venoarterial extracorporeal mem
directed to the systemic circulation through an 8-mmDacron polyester fabric gra
left ventricular assist device outflow graft.
e32 The Journal of Thoracic and Cardiovascular Surgvenoarterial ECMO support to have any more bleeding
complications and blood product transfusions than did
patients with HM II placement alone.
De Silva and coworkers4 described a peripheral RVAD
technique through an ECMO system to allow closed-chest
explantation. Although this approach does facilitate
RVAD explantation, it does not confer the advantage of
unloading the RV as does ECMO with outflow to the
systemic circulation, as described here.
Peripheral venoarterial ECMO for RHF after LVAD im-
plantation was described by Scherer and colleagues.5 All
10 of their patients were weaned from ECMO, although 4
patients died while receiving LVAD support. We have also
found this approach useful in our patients; however, in cases
of (1) central aortic cannulation, (2) subclavian artery steno-
sis, or (3) axillary artery diameter inadequate for ECMO
flow, the strategy of coupling ECMO and LVAD outflow
grafts (Figure 1) offers a simple solution for central
systemic perfusion.
We believe that this management strategy of venoarterial
ECMO configured for easy explantation may improve RV
recovery and reduce the postoperative complications andbrane oxygenation. The extracorporeal membrane oxygenation outflow is
ft, which is tunneled through the right pleural cavity and anastomosed to the
ery c March 2014
Case Reportsmortality associated with RHF complicating LVAD
implantation.
We thank Drs Alan Gass and Gregg Lanier for their contribu-
tions to this study.
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